{"protocolSection": {"identificationModule": {"nctId": "NCT02002221", "orgStudyIdInfo": {"id": "CLAF237A1405"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients", "officialTitle": "A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2016-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-12"}, "primaryCompletionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-11-29", "studyFirstSubmitQcDate": "2013-11-29", "studyFirstPostDateStruct": {"date": "2013-12-05", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-02-02", "resultsFirstSubmitQcDate": "2016-02-02", "resultsFirstPostDateStruct": {"date": "2016-03-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-02-02", "lastUpdatePostDateStruct": {"date": "2016-03-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study was to assess the efficacy and safety of vildagliptin 50 mg bid add-on therapy to improve overall glycemic control in patients with T2DM inadequately controlled by insulin, with or without concomitant metformin treatment. It was agreed with PMDA to conduct a postmarketing clinical trial to further collect the efficacy and safety data of vildagliptin especially in Japanese patients when it iwas used on top of insulin."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus (T2DM)"], "keywords": ["Diabetes Mellitus (DM) ,", "diabetes,", "noninsulin-dependent diabetes mellitus (NIDDM),", "adult-onset diabetes,", "high blood sugar,", "T2DM"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 156, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Vildagliptin (LAF237)", "type": "EXPERIMENTAL", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study", "interventionNames": ["Drug: Vildagliptin (LAF237)", "Drug: Insulin", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study", "interventionNames": ["Drug: Placebo", "Drug: Insulin", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Vildagliptin (LAF237)", "description": "Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily", "armGroupLabels": ["Vildagliptin (LAF237)"], "otherNames": ["Vildagliptin"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo of vildagliptin 50 mg twice daily", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Insulin", "description": "Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.\n\nThe insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion.", "armGroupLabels": ["Placebo", "Vildagliptin (LAF237)"]}, {"type": "DRUG", "name": "Metformin", "description": "Patients continued their prescribed metformin dose, if applicable.", "armGroupLabels": ["Placebo", "Vildagliptin (LAF237)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks Between Treatment Groups", "description": "HbA1c was performed on a blood sample obtained and measured by high performance liquid chromatography performed at a central laboratory.", "timeFrame": "Baseline, week 12"}], "secondaryOutcomes": [{"measure": "Percentage of Patients Meeting Responder Rates in HbA1c", "description": "Responder rate was analyzed in categories: Criterion 1- Endpoint HbA1c \u2264 6.5%, Criterion 2- Endpoint HbA1c \\< 7% , Criterion 3- Endpoint HbA1c \\< 7% in patients with baseline HbA1c \u2264 8%, Criterion 4- HbA1c reduction from baseline at endpoint \u2265 1%, Criterion 5- HbA1c reduction from baseline at endpoint \u2265 0.5%. The number of patients analyzed for Criterion 1 and 2 include only patients with baseline HbA1c \u2265 7% (\\> 6.5%) and endpoint HbA1c measurement. The number of patients analyzed for Criterion 3 includes only patients with 7% \u2264 baseline HbA1c \u2264 8% and endpoint HbA1c measurement. The number of patients analyzed for Criterion 4 and 5 include patients with both baseline and endpoint HbA1c measurements.", "timeFrame": "Baseline, week 12"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at 12 Weeks", "description": "FPG was performed on a blood sample obtained and analyzed at a central laboratory.", "timeFrame": "Baseline, week 12"}, {"measure": "Number of Participants With Incidence of Hypoglycemia and Severe Hypoglycemia", "description": "Hypoglycemic events are defined as a) symptoms suggestive of hypoglycemia, where the patient is able to initiate self-treatment and plasma glucose measurement is \\< 56 mg/dL (grade 1), b) symptoms suggestive of hypoglycemia, where the patient is unable to initiate self-treatment and plasma glucose measurement is \\< 56 mg/dL (grade 2), c) symptoms suggestive of hypoglycemia, where the patient is unable to initiate self-treatment and no plasma glucose measurement is available (suspected grade 2)", "timeFrame": "12 weeks"}, {"measure": "Number of Participants With Adverse Events, Serious Adverse Events and Death", "description": "The occurrence of adverse events was sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, vital sign, or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of T2DM by standard criteria.\n* HbA1c \u2265 7.0 to \u2264 10% at Visit 1.\n* Age: \u2265 20 to \\< 75 years old at Visit 1.\n* BMI \u2265 20 to \u2264 35 kg/m2 at Visit 1.\n\nExclusion Criteria:\n\n* FPG \u2265 270 mg/dL (\u226515 mmol/L) at Visit 1.\n* Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes.\n* Significant heart diseases\n* Hepatic disorder\n\nOther protocol defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "74 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Fukuoka-city", "state": "Fukuoka", "zip": "810-8798", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Novartis Investigative Site", "city": "Fukuoka-city", "state": "Fukuoka", "zip": "815-0071", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Novartis Investigative Site", "city": "Fukutsu-city", "state": "Fukuoka", "zip": "811-3217", "country": "Japan", "geoPoint": {"lat": 33.783, "lon": 130.49114}}, {"facility": "Novartis Investigative Site", "city": "Kitakyushu-city", "state": "Fukuoka", "zip": "800-0295", "country": "Japan", "geoPoint": {"lat": 33.85181, "lon": 130.85034}}, {"facility": "Novartis Investigative Site", "city": "Koriyama-city", "state": "Fukushima", "zip": "963-8851", "country": "Japan", "geoPoint": {"lat": 37.4, "lon": 140.38333}}, {"facility": "Novartis Investigative Site", "city": "Mito-city", "state": "Ibaraki", "zip": "311-4153", "country": "Japan", "geoPoint": {"lat": 36.35, "lon": 140.45}}, {"facility": "Novartis Investigative Site", "city": "Ibusuki-city", "state": "Kagoshima", "zip": "891-0401", "country": "Japan", "geoPoint": {"lat": 31.23333, "lon": 130.65}}, {"facility": "Novartis Investigative Site", "city": "Yokohama-city", "state": "Kanagawa", "zip": "221-0802", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Kumamoto-city", "state": "Kumamoto", "zip": "861-8039", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "Novartis Investigative Site", "city": "Kumamoto-city", "state": "Kumamoto", "zip": "861-8520", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "Novartis Investigative Site", "city": "Yatsushiro-city", "state": "Kumamoto", "zip": "866-8533", "country": "Japan", "geoPoint": {"lat": 32.55723, "lon": 130.65285}}, {"facility": "Novartis Investigative Site", "city": "Kyoto-city", "state": "Kyoto", "zip": "615-0035", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Novartis Investigative Site", "city": "Sendai-city", "state": "Miyagi", "zip": "980-0021", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "Novartis Investigative Site", "city": "Hirakata-City", "state": "Osaka", "zip": "573-0153", "country": "Japan", "geoPoint": {"lat": 34.81352, "lon": 135.64914}}, {"facility": "Novartis Investigative Site", "city": "Izumisano-city", "state": "Osaka", "zip": "598-8577", "country": "Japan", "geoPoint": {"lat": 34.41663, "lon": 135.31667}}, {"facility": "Novartis Investigative Site", "city": "Osaka-city", "state": "Osaka", "zip": "530-0001", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Novartis Investigative Site", "city": "Osaka-city", "state": "Osaka", "zip": "534-0021", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Novartis Investigative Site", "city": "Takatsuki-city", "state": "Osaka", "zip": "569-1096", "country": "Japan", "geoPoint": {"lat": 34.84833, "lon": 135.61678}}, {"facility": "Novartis Investigative Site", "city": "Ageo-city", "state": "Saitama", "zip": "362-8588", "country": "Japan", "geoPoint": {"lat": 35.97145, "lon": 139.61382}}, {"facility": "Novartis Investigative Site", "city": "Saitama-city", "state": "Saitama", "zip": "336-0963", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "Novartis Investigative Site", "city": "Sayama-city", "state": "Saitama", "zip": "350-1305", "country": "Japan", "geoPoint": {"lat": 35.85295, "lon": 139.41212}}, {"facility": "Novartis Investigative Site", "city": "Tokorozawa-city", "state": "Saitama", "zip": "359-1161", "country": "Japan", "geoPoint": {"lat": 35.79916, "lon": 139.46903}}, {"facility": "Novartis Investigative Site", "city": "Adachi-ku", "state": "Tokyo", "zip": "123-0845", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Chiyoda-ku", "state": "Tokyo", "zip": "101-0024", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Chuo-ku", "state": "Tokyo", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Novartis Investigative Site", "city": "Chuo-ku", "state": "Tokyo", "zip": "103-0028", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Novartis Investigative Site", "city": "Chuo-ku", "state": "Tokyo", "zip": "104-0061", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Novartis Investigative Site", "city": "Nerima-ku", "state": "Tokyo", "zip": "177-0041", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Nerima-ku", "state": "Tokyo", "zip": "177-0051", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Ota-ku", "state": "Tokyo", "zip": "144-0051", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Novartis Investigative Site", "city": "Suginami-ku", "state": "Tokyo", "zip": "166-0004", "country": "Japan"}]}, "referencesModule": {"references": [{"pmid": "26620049", "type": "DERIVED", "citation": "Hirose T, Suzuki M, Tsumiyama I. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study. Diabetes Ther. 2015 Dec;6(4):559-571. doi: 10.1007/s13300-015-0147-6. Epub 2015 Nov 30."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Vildagliptin (LAF237)", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}, {"id": "FG001", "title": "Placebo", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "78"}, {"groupId": "FG001", "numSubjects": "78"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "76"}, {"groupId": "FG001", "numSubjects": "75"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Patient withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Vildagliptin (LAF237)", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}, {"id": "BG001", "title": "Placebo", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "78"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "156"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.5", "spread": "9.57"}, {"groupId": "BG001", "value": "60.1", "spread": "9.11"}, {"groupId": "BG002", "value": "59.3", "spread": "9.34"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "45"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "111"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks Between Treatment Groups", "description": "HbA1c was performed on a blood sample obtained and measured by high performance liquid chromatography performed at a central laboratory.", "populationDescription": "The full analysis set consisted of all randomized patients who received at least one dose of study medication and had at least one post-baseline assessment of efficacy parameter measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Baseline, week 12", "groups": [{"id": "OG000", "title": "Vildagliptin (LAF237)", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}, {"id": "OG001", "title": "Placebo", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.01", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.11", "spread": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: \u03b4 vildagliptin 50 mg bid = \u03b4 placebo versus H1: \u03b4 Vildagliptin 50 mg bid \\< \u03b4 placebo,", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "< 0.001", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Net)", "paramValue": "-0.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.08", "ciUpperLimit": "-0.73", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.09"}]}, {"type": "SECONDARY", "title": "Percentage of Patients Meeting Responder Rates in HbA1c", "description": "Responder rate was analyzed in categories: Criterion 1- Endpoint HbA1c \u2264 6.5%, Criterion 2- Endpoint HbA1c \\< 7% , Criterion 3- Endpoint HbA1c \\< 7% in patients with baseline HbA1c \u2264 8%, Criterion 4- HbA1c reduction from baseline at endpoint \u2265 1%, Criterion 5- HbA1c reduction from baseline at endpoint \u2265 0.5%. The number of patients analyzed for Criterion 1 and 2 include only patients with baseline HbA1c \u2265 7% (\\> 6.5%) and endpoint HbA1c measurement. The number of patients analyzed for Criterion 3 includes only patients with 7% \u2264 baseline HbA1c \u2264 8% and endpoint HbA1c measurement. The number of patients analyzed for Criterion 4 and 5 include patients with both baseline and endpoint HbA1c measurements.", "populationDescription": "The full analysis set consisted of all randomized patients who received at least one dose of study medication and had at least one post-baseline assessment of efficacy parameter measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "Baseline, week 12", "groups": [{"id": "OG000", "title": "Vildagliptin (LAF237)", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}, {"id": "OG001", "title": "Placebo", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"title": "At least one criterion met (n = 78, 78)", "categories": [{"measurements": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Criterion 1 (n= 77, 78)", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Criterion 2 (n= 76, 77)", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Criterion 3 (n= 42, 37)", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Criterion 4 (n=78, 78)", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Criterion 5 (n= 78, 78)", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "20"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at 12 Weeks", "description": "FPG was performed on a blood sample obtained and analyzed at a central laboratory.", "populationDescription": "The full analysis set consisted of all randomized patients who received at least one dose of study medication and had at least one post-baseline assessment of efficacy parameter measurement. Number of patients with observations at both baseline and endpoint are analyzed in this endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, week 12", "groups": [{"id": "OG000", "title": "Vildagliptin (LAF237)", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}, {"id": "OG001", "title": "Placebo", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21.87", "spread": "4.05"}, {"groupId": "OG001", "value": "-0.30", "spread": "4.04"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Incidence of Hypoglycemia and Severe Hypoglycemia", "description": "Hypoglycemic events are defined as a) symptoms suggestive of hypoglycemia, where the patient is able to initiate self-treatment and plasma glucose measurement is \\< 56 mg/dL (grade 1), b) symptoms suggestive of hypoglycemia, where the patient is unable to initiate self-treatment and plasma glucose measurement is \\< 56 mg/dL (grade 2), c) symptoms suggestive of hypoglycemia, where the patient is unable to initiate self-treatment and no plasma glucose measurement is available (suspected grade 2)", "populationDescription": "The safety set consisted of all patients who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Vildagliptin (LAF237)", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}, {"id": "OG001", "title": "Placebo", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"title": "at least one hypoglycemic event", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "grade 2 hypoglycemic events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "suspected grade 2 hypoglycemic events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events, Serious Adverse Events and Death", "description": "The occurrence of adverse events was sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, vital sign, or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.", "populationDescription": "The safety set consisted of all patients who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Vildagliptin (LAF237)", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}, {"id": "OG001", "title": "Placebo", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "78"}, {"groupId": "OG001", "value": "78"}]}], "classes": [{"title": "Any adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "34"}]}]}, {"title": "Serious adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "The safety set consisted of all patients who received at least one dose of study medication. Patients were analyzed according to the treatment received.", "eventGroups": [{"id": "EG000", "title": "Vildagliptin (LAF237)", "description": "Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study", "seriousNumAffected": 2, "seriousNumAtRisk": 78, "otherNumAffected": 22, "otherNumAtRisk": 78}, {"id": "EG001", "title": "Placebo", "description": "In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study", "seriousNumAffected": 1, "seriousNumAtRisk": 78, "otherNumAffected": 21, "otherNumAtRisk": 78}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Femoral neck fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 78}]}, {"term": "Squamous cell carcinoma of the tongue", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 78}]}], "otherEvents": [{"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 78}]}, {"term": "Hunger", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 78}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 78}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 78}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 78}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 78}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 78}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "trialandresults.registries@novartis.com", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M9994", "name": "Hyperglycemia", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077597", "term": "Vildagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M1857", "name": "Vildagliptin", "asFound": "100%", "relevance": "HIGH"}, {"id": "M29799", "name": "Biphasic Insulins", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}